Evidence map›Paper›PMID 33898325›Full record

ArticleFrontiers in oncology2021

Corrigendum: Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease.

Larissa Di Villeneuve, Ive Lima Souza, Fernanda Davila Sampaio Tolentino, Renata Ferrarotto, Gustavo Schvartsman

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Larissa Di VilleneuveDepartment of Medical Oncology, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Ive Lima SouzaDepartment of Medical Oncology, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Fernanda Davila Sampaio TolentinoDepartment of Medical Oncology, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Renata FerrarottoDepartment of Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Gustavo SchvartsmanDepartment of Medical Oncology, Hospital Israelita Albert Einstein, São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fonc.2020.580141.].

Indexed as

androgen receptordrug resistanceERBB-2 receptorgene fusionimmunotherapymolecular targeted therapysalivary gland cancer

Identifiers

PMID33898325
PMCPMC8063728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.